Zepbound bests Wegovy for weight loss in new trial

Posted on: 05-Jan-2025

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

8 Salt Creek Lane
Hinsdale, IL 60521

Mon - Fri : 09.00 am - 06.00 pm
Sat - Sun : Closed

875 North Michigan Ave.
31st Floor
Chicago, IL 60611

[javascript protected email address]